REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedHuman TrialHuman Subjects

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen Anders Boisen, Renström Frida, Aczél Stefan, Folie Patrick, Biraima-Steinemann Magdalena, Beuschlein Felix, Bilz Stefan
Obesity surgery2023DOI: 10.1007/s11695-023-06484-8
GLP1-RALiraglutideSemaglutide

Quality Score

6/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

Human trial data is the most directly translatable evidence for therapeutic applications. The physiological responses observed here reflect real human biology, not extrapolations from animal models.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for GLP1-RA, Liraglutide, Semaglutide are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the sample size is modest, which limits statistical power and the ability to detect smaller but clinically meaningful effects; data from a single center may not generalize across different populations or clinical settings. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GLP1-RA, Liraglutide, Semaglutide. Not the final word, but a meaningful data point that adds to the weight of evidence.

Key Findings

The study found that GLP1-RA, including liraglutide and semaglutide, can help patients who have regained weight after bariatric surgery to lose a significant portion of the regained weight within six months.

Limitations

This was a single-center retrospective observational study with a relatively small sample size, which limits its generalizability. The lack of randomization means that there could be confounding variables affecting the results.

PeptideVault Analysis

Highlighting the potential of GLP1-RA as an effective treatment for weight regain following bariatric surgery and discussing its implications for clinical practice.

GLP1-RALiraglutideSemaglutide

GLP-1 Receptor Agonists Show Promise in Tackling Weight Regain After Bariatric Surgery

Published: May 17, 2026 | Source: Obesity surgery (2023) | Category: GLP1-RA, Liraglutide, Semaglutide

Overview

A recent study published in Obesity Surgery suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as liraglutide and semaglutide, can help patients who have regained weight after bariatric surgery to lose a significant portion of the regained weight within six months. This finding is crucial for those seeking effective treatments for weight regain following surgical interventions.

Study Background

Weight regain after bariatric surgery is a common issue, affecting up to one-third of patients. While GLP-1 RAs are known to be effective in managing type 2 diabetes and obesity, their role in treating weight regain specifically after bariatric surgery was less clear until now. This retrospective observational study aimed to fill this knowledge gap by examining the efficacy of liraglutide and semaglutide for patients who had regained weight post-surgery.

What the Research Found

The study involved 50 patients (82% female) at a Swiss bariatric reference center, with an average age of 47 years. Before treatment with GLP-1 RAs, these patients had an average body weight of 90.5 kg and a BMI of 34.0 kg/m². After six months of treatment (liraglutide: n=29; semaglutide: n=21), the median weight loss was substantial, with two-thirds of the regained weight being lost.

What This Means for Peptide Users

For individuals who have experienced weight regain after bariatric surgery, this study provides hope and a new therapeutic option. GLP-1 RAs can be an effective tool in helping these patients achieve significant weight loss, thereby improving their overall health outcomes and reducing the risk of obesity-related complications.

Limitations and Caveats

While promising, this study has several limitations that must be acknowledged. It was conducted at a single center with a relatively small sample size, which limits its generalizability to broader populations. Additionally, the retrospective nature of the research means there could be uncontrolled variables influencing the results. Randomized controlled trials are needed to confirm these findings and establish GLP-1 RAs as standard treatment options for weight regain after bariatric surgery.

How This Compares to Previous Research

Previous studies have highlighted the efficacy of GLP-1 RAs in treating obesity and type 2 diabetes, but this is one of the first to focus specifically on their role in managing weight regain post-bariatric surgery. The results align with earlier research showing that these peptides can induce significant weight loss, although the specific context of bariatric surgery adds a new dimension to our understanding.

Our Analysis

PeptideVault views this study as an important step forward in addressing the challenges faced by patients who experience weight regain after bariatric surgery. The findings are encouraging and provide a basis for further research. However, due to the limitations mentioned, it is crucial that future studies employ randomized controlled trial designs to validate these results.

Key Takeaways

  • GLP-1 RAs can help patients lose significant amounts of regained weight within six months after bariatric surgery.
  • The study highlights a need for larger-scale clinical trials to confirm the efficacy and safety of GLP-1 RAs in this specific patient population.
  • For now, healthcare providers should consider these findings as part of an evolving understanding of GLP-1 RA's potential benefits beyond traditional indications like diabetes and obesity.

Original Source

Citation: Jensen Anders Boisen, Renström Frida, Aczél Stefan et al. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.. Obesity surgery. DOI: 10.1007/s11695-023-06484-8

Access: https://pubmed.ncbi.nlm.nih.gov/36765019/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on GLP1-RA, explore our research guides.

Citation

Jensen Anders Boisen, Renström Frida, Aczél Stefan et al.. (2023). Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.. Obesity surgery. https://doi.org/10.1007/s11695-023-06484-8

View full text on PubMed

Related Papers

Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.

Irfan Hamza · Current problems in cardiology · 2024

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.